The key to this therapeutic strategy is to enable specialised expression of HSV-tk at glioma sites to convert non-toxic GCV to its toxic metabolite, GCV-triphosphate (GCV-3P), and deliver GCV-3P for selected elimination of tumour cells through the bystander effect. The gene discussed is TKT; the disease is glioma.